share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股SEC公告 ·  07/16 16:08
Moomoo AI 已提取核心訊息
On July 16, 2024, Senti Biosciences, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol SNTI, reported the entry into an amended and restated ChEF purchase agreement with Chardan Capital Markets LLC. This agreement pertains to Senti Biosciences' existing $50 million equity facility and includes updated volume weighted average price purchase mechanics to allow for Intraday VWAP Purchases. The details of the amended agreement were summarized in the company's Form 8-K filing with the SEC, with the full text of the agreement attached as Exhibit 10.1. Senti Biosciences, identified as an emerging growth company, has also elected not to use the extended transition period for complying with new or revised financial accounting standards. The company's CEO, Timothy Lu, M.D., Ph.D., signed the SEC filing on the same day, affirming the company's compliance with the Securities Exchange Act of 1934.
On July 16, 2024, Senti Biosciences, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol SNTI, reported the entry into an amended and restated ChEF purchase agreement with Chardan Capital Markets LLC. This agreement pertains to Senti Biosciences' existing $50 million equity facility and includes updated volume weighted average price purchase mechanics to allow for Intraday VWAP Purchases. The details of the amended agreement were summarized in the company's Form 8-K filing with the SEC, with the full text of the agreement attached as Exhibit 10.1. Senti Biosciences, identified as an emerging growth company, has also elected not to use the extended transition period for complying with new or revised financial accounting standards. The company's CEO, Timothy Lu, M.D., Ph.D., signed the SEC filing on the same day, affirming the company's compliance with the Securities Exchange Act of 1934.
2024年7月16日，美國特拉華州公司Senti Biosciences在納斯達克資本市場上市，交易代碼爲SNTI。該公司與Chardan Capital Markets LLC簽訂了一份經過修訂和重新簽署的股權購買協議，涉及Senti Biosciences現有的500萬美元股權配售，並更新了成交量加權平均價格購買機制，以便進行日內成交量加權平均價格購買。修訂後的協議詳情在該公司提交給美國證監會的8-K表格中概述，附有協議全文作爲10.1展品。作爲新興成長公司，Senti Biosciences還選擇不使用延長的過渡期來符合新的或修訂的財務會計標準。該公司的首席執行官魯萬第博士於當天簽署了該SEC文件，確認公司遵守1934年的證券交易法規。
2024年7月16日，美國特拉華州公司Senti Biosciences在納斯達克資本市場上市，交易代碼爲SNTI。該公司與Chardan Capital Markets LLC簽訂了一份經過修訂和重新簽署的股權購買協議，涉及Senti Biosciences現有的500萬美元股權配售，並更新了成交量加權平均價格購買機制，以便進行日內成交量加權平均價格購買。修訂後的協議詳情在該公司提交給美國證監會的8-K表格中概述，附有協議全文作爲10.1展品。作爲新興成長公司，Senti Biosciences還選擇不使用延長的過渡期來符合新的或修訂的財務會計標準。該公司的首席執行官魯萬第博士於當天簽署了該SEC文件，確認公司遵守1934年的證券交易法規。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息